Key points are not available for this paper at this time.
In this issue of the Journal, Tahaoğlu and coworkers report on their experience in treating a cohort of patients infected with strains of Mycobacterium tuberculosis that are resistant to powerful antituberculosis drugs. Tuberculosis caused by strains that are resistant to at least isoniazid and rifampin is, by convention, termed “multidrug-resistant tuberculosis.”1 The authors of this report work in a referral center in Turkey that has available a full complement of clinical, laboratory, and surgical services, including multidrug treatment regimens given for 18 to 24 months, resources for the management of side effects, adjuvant surgery when necessary, and full financial and . . .
Paul Farmer (Thu,) studied this question.